AI assistant
Sending…
Vivos Therapeutics, Inc. — Director's Dealing 2021
Aug 11, 2021
34780_dirs_2021-08-10_b9fef9c7-53ca-4f71-881c-49a84fff1dea.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vivos Therapeutics, Inc. (VVOS)
CIK: 0001716166
Period of Report: 2021-08-05
Reporting Person: Lindsay Mark F. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-05 | Stock Option (Right to Buy) | $2.72 | A | 30000 | Acquired | 2026-08-05 | Common Stock (46667) | Direct |
Footnotes
F1: 30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022.
More from Vivos Therapeutics, Inc.
Interim / Quarterly Report
2026
May 20
Regulatory Filings
2026
May 8
Delisting Announcement
2026
Apr 22
Regulatory Filings
2026
Apr 15
Annual Report
2026
Apr 15
Capital/Financing Update
2026
Apr 3
Capital/Financing Update
2026
Feb 14
Director's Dealing
2026
Feb 13
Board/Management Information
2026
Feb 6
Capital/Financing Update
2026
Jan 20